Enhancing Motivation in Recent Onset Schizophrenia

Schizophrenia Clinical Trial

— PRIME  

Official title:

Developing an Intervention Strategy to Enhance Motivation in Recent Onset Schizophrenia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01817387
• Other study ID #: NIMHK23SCH
• Status: Terminated
• Phase: N/A
• Start date: July 2014
• Est. completion date: March 20, 2018

Study information

• Verified date: January 2020
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This project will result in the development of a personalized intervention strategy to improve motivation for treatment engagement and functional outcomes in individuals with a recent onset of schizophrenia. Motivational impairment is arguably the single most important factor that determines a patient's ability to engage in and adhere to effective treatment. In our study, sixty participants will be enrolled in a randomized controlled trial comparing the feasibility and tolerability of two types of motivational interventions (Daily Goals or PRIME), and a neuroplasticity-based cognitive training program. Participants are randomized to either receive Daily Goals or PRIME for 8 weeks, after which, both conditions will also receive an 8-week course of cognitive training delivered via iPads. Participants will undergo pre/post-testing and a 6-month follow-up to determine feasibility and efficacy of the interventions. By enhancing motivation, schizophrenia patients would be able to engage more fully with treatment and develop full and productive lives. This study may also pave the way forward for other health conditions in which motivational impairments impede health outcomes.

All assessments will be conducted at the University of California, San Francisco; however, we offer some assessments to be done remotely.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: March 20, 2018
• Est. primary completion date: March 20, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 30 Years

Eligibility

Inclusion Criteria:

• Diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder.

• Onset of diagnosis within 5 years.

• 14-30 years old.

• Clinically stable (outpatient status for 1 month and stable dose of medication for 1 month).

• Good general health

Exclusion Criteria:

• Substance dependence within the past 12 months,

• Current substance abuse,

• No history of neurological disorder

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Behavioral:
• PRIME
Mobile application designed to improve psychosocial functioning and motivational deficits
• Cognitive Training
Auditory processing, verbal learning, memory, processing speed, and social cognition

Locations

Country	Name	City	State
United States	University of California San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Psychosocial functioning	Work status, work performance, social status, social performance, health status, health performance	past 30 days

External Links

•   Lab website